Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredients in Maymetsi, are a biguanide/DPP‑4 inhibitor combination presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adults.

GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maymetsi, a fixed‑dose combination of metformin and sitagliptin, is indicated for the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control when diet, exercise and monotherapy are insufficient. - Adults with inadequate response to metformin alone: provides additional glucose‑lowering effect. - Patients requiring combination therapy: simplifies regimen by delivering two agents in one tablet.

Common Side Effects: - Gastrointestinal upset (nausea, diarrhoea, abdominal discomfort) - Headache - Upper respiratory tract infection - Metallic taste - Mild hypoglycaemia when combined with other antidiabetics

Serious or Rare Side Effects: - Lactic acidosis (metformin‑related) - Severe hypersensitivity reactions (rash, angio‑edema, anaphylaxis) - Pancreatitis - Hepatic dysfunction - Renal impairment worsening

Maymetsi should be used with caution in patients with renal or hepatic impairment and in the elderly.

- Renal function: assess eGFR before initiation and periodically thereafter. - Hepatic disease: avoid in patients with significant liver dysfunction. - Cardiovascular risk: monitor for signs of heart failure. - Pregnancy and lactation: only if clearly needed, after risk‑benefit assessment. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Maymetsi may interact with several drug classes that affect glucose metabolism or renal clearance.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure. - Alcohol excess: heightens risk of metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics and ACE inhibitors: may affect renal function, requiring dose adjustment. - Beta‑blockers: can mask hypoglycaemia symptoms. - Other antidiabetic agents: increase risk of hypoglycaemia, necessitating glucose monitoring.